Filing Analysis
Orchestra BioMed Holdings, Inc. held its 2026 Annual Meeting of Stockholders on June 23, 2026. The meeting resulted in the successful election of three Class III directors and the approval of several key shareholder proposals.
📋 Key Facts
- Annual Meeting held on June 23, 2026.
- Total shares entitled to vote: 59,880,715; Shares represented at meeting: 49,053,298.
- Elected David P. Hochman, Darren R. Sherman, and Eric S. Fain as Class III directors until the 2029 annual meeting.
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2026.
- Approved the 2026 Equity Incentive Plan (ESPP Proposal).
- Stockholders approved executive compensation on an advisory basis and voted to maintain a '1 Year' frequency for say-on-pay votes.
Orchestra BioMed Holdings announced the adoption of a 2026 cash bonus plan for executive officers and updates to compensation structures. The plan is tied to clinical trial milestones (BACKBEAT and Virtue SAB) and financial objectives.
🚩 Red Flags
- Increased executive compensation (salaries and bonus percentages) during a period where clinical milestones are the primary driver of value.
📋 Key Facts
- Board approved the 2026 Cash Bonus Plan on February 12, 2026.
- Bonus structure includes mid-year performance reviews with up to 25% payout in Q3 2026 and up to 75% based on full-year results in Q1 2027.
- Performance metrics are tied to BACKBEAT (Bradycardia Marker) and Virtue SAB (Sirolimus AngioInfusion Balloon) pivotal study enrollment targets.
- CEO Hochman received a 4% base salary increase and target bonus increased from 80% to 100% of base salary.
- President/COO Sherman received a 10% base salary increase and target bonus increased from 80% to 90% of base salary.
- Revised RSU vesting schedule: four equal installments at 18, 24, 30, and 36 months.
Orchestra BioMed Holdings, Inc. announced a significant asset acquisition involving the receipt of up to $21 million in proceeds from Haemonetics' acquisition of Vivasure.
📋 Key Facts
- The company will receive up to $21 million in proceeds related to the acquisition of Vivasure by Haemonetics.
- Announcement date: January 12, 2026.
- The filing includes a press release (Exhibit 99.1) detailing the transaction.
Orchestra BioMed Holdings, Inc. held a conference call on November 12, 2025, to discuss significant business updates regarding clinical, strategic, and financing developments. The company provided a transcript and an investor presentation as exhibits to this filing.
📋 Key Facts
- Conference call held on November 12, 2025, via live audio and video webcast.
- Updates covered clinical, strategic, and financing developments.
- The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
Orchestra BioMed Holdings, Inc. filed an 8-K to provide a copy of its investor and industry conference slide presentation via Exhibit 99.1.
📋 Key Facts
- The filing is made under Item 7.01 (Regulation FD Disclosure).
- The company provided a slide presentation used at conferences as an exhibit.
- The information in the presentation is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Orchestra BioMed Holdings entered into a termination and ROFR agreement with Terumo Medical Corporation, alongside a $20 million private placement of Series A Convertible Preferred Stock to TMC. The deal includes a significant Right of First Refusal (ROFR) granted to Terumo regarding the company's Virtue SAB product candidate.
🚩 Red Flags
- Significant dilution potential: The 200,000 preferred shares could convert into up to 1,666,666 shares of common stock.
- Restrictive ROFR: Terumo's Right of First Refusal on the flagship Virtue SAB product may deter other strategic acquirers or licensees.
- Liquidation preference: Series A holders have a $100/share liquidation preference, which sits ahead of common shareholders in a sale or dissolution.
📋 Key Facts
- Terumo Medical Corporation (TMC) to purchase 200,000 shares of Series A Convertible Preferred Stock at $100.00 per share, totaling $20 million in gross proceeds.
- The transaction includes a $10 million ROFR fee payable by Orchestra to Terumo within 10 business days of the effective date (October 24, 2025).
- Terumo is granted a Right of First Refusal (ROFR) on any third-party proposals for the acquisition or licensing of 'Virtue SAB' in coronary artery disease indications.
- The ROFR period lasts until 90 days after primary endpoint data from the U.S. clinical trial for Virtue SAB is disclosed, or up to a 10-year maximum.
- Series A Preferred Stock features a conversion price equal to the greater of $12.00 per share or a 20% discount to the Nasdaq closing price.
- The Series A shares have a liquidation value of $100.00 per share, providing significant downside protection relative to common stock.
Orchestra BioMed Holdings, Inc. completed a significant dual-track financing consisting of a $40 million public offering and a $16.2 million private placement (PIPE). The funds are earmarked for clinical development programs including the BACKBEAT study and Virtue SAB trial.
🚩 Red Flags
- Significant dilution via the issuance of over 9.4 million new shares and 5.1 million pre-funded warrants.
- Pre-funded warrants allow investors to delay equity conversion while maintaining economic exposure, often a sign of non-traditional financing needs.
📋 Key Facts
- Public Offering: 9,413,637 shares of common stock at $2.75 per share.
- Pre-Funded Warrants: Up to 5,136,363 warrants issued at $2.7499 per warrant (representing the offering price less $0.0001 exercise price).
- Private Placement (PIPE): 5,895,608 shares sold to Ligand Pharmaceuticals and Covidien Group S.à.r.l. for ~$16.2 million.
- Gross Proceeds: Approximately $40 million from the public offering (before expenses) plus $16.2 million from the PIPE.
- Warrant Issuance: Issued a warrant to Ligand Pharmaceuticals to purchase up to 2,000,000 shares at an exercise price of $3.67 per share.
- Use of Proceeds: Funding for atrioventricular interval modulation therapy, BACKBEAT study, Virtue Sirolimus AngioInfusion Balloon (SAB) program, and clinical development.
Orchestra BioMed Holdings has entered into a complex multi-party financing structure involving Ligand Pharmaceuticals and Medtronic, including a $35 million revenue participation agreement and a $20 million convertible loan. The deal includes significant equity warrants and private placements contingent upon the success of an upcoming public offering.
🚩 Red Flags
- Complex financing structure with multiple layers of subordination and contingent milestones.
- Performance Ratchet: Revenue interest rates increase if clinical enrollment milestones are not met by Jan 1, 2027.
- Significant dilution risk via warrants (2M shares) and private placements to major partners.
- Heavy reliance on the success of a 'Subsequent Offering' to trigger the closing of these agreements.
📋 Key Facts
- Entered into a Revenue Purchase and Sale Agreement with Ligand Pharmaceuticals for $35.0 million, payable in two tranches ($20M at closing; $15M after 270 days).
- Ligand to receive tiered revenue interest (4% to 17%, potentially increasing up to 20% via a 'Performance Ratchet' if clinical milestones are missed).
- Ligand granted warrants to purchase up to 2,000,000 shares of common stock at a 30% premium.
- Medtronic agreed to a $20.0 million convertible loan (11% interest) maturing April 27, 2031, with potential conversion into revenue share credits upon FDA approval of AVIM therapy.
- Private placements: Ligand to purchase $5.0 million in common stock; Medtronic/Covidien to purchase up to $12.0 million in common stock.
- All transactions are contingent upon the closing of a 'Subsequent Offering' (public offering) and achieving aggregate gross proceeds thresholds ($30M-$35M range).
- The revenue interest is secured by interests in products and IP, subordinate to existing Hercules Loan Agreement debt.
Orchestra BioMed Holdings, Inc. held its 2025 Annual Meeting of Stockholders on June 24, 2025. The meeting resulted in the successful election of three Class II directors and the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 24, 2025.
- Total shares entitled to vote: 38,312,512 (as of April 28, 2025 record date).
- Shares represented at meeting: 28,177,159.
- Three Class II directors elected: Chris Cleary, Pamela Connealy, and David Pacitti, to serve until the 2028 annual meeting.
- Proposal to ratify Ernst & Young LLP as independent auditor for fiscal year ending Dec 31, 2025 was approved.
Orchestra BioMed Holdings announced two significant regulatory milestones: FDA Breakthrough Device Designation for its AVIM therapy and an IDE amendment to initiate the Virtue clinical trial for its Virtue SAB product candidate.
🚩 Red Flags
- No significant red flags detected; filing consists of positive regulatory updates.
📋 Key Facts
- FDA granted Breakthrough Device Designation (BDD) for Atrioventricular Interval Modulation (AVIM) therapy to treat hypertension in pacemaker patients.
- The AVIM therapy is being evaluated in the BACKBEAT global pivotal study in collaboration with Medtronic.
- FDA approved an IDE amendment for the Virtue Trial, a U.S. pivotal clinical trial for Virtue SAB (Sirolimus Infusion™ Balloon).
- The Virtue Trial aims to randomize 740 patients across up to 75 centers in the US, targeting initiation in H2 2025.
- Virtue SAB is designed to compare against Boston Scientific's AGENT paclitaxel-coated balloon.
Orchestra BioMed Holdings, Inc. filed an 8-K to provide a copy of a slide presentation used at investor and industry conferences under Regulation FD disclosure.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- A slide presentation was attached as Exhibit 99.1 for investor/industry conference use.
- The information in the presentation is furnished but not 'filed' under Section 18 of the Exchange Act.
Orchestra BioMed Holdings announced several updates to its executive compensation structures on February 19, 2025. These include a new tax withholding policy for RSU vesting, the implementation of a mid-year performance-based cash bonus plan, and revised equity award/vesting policies designed to incentivize long-term retention.
🚩 Red Flags
- The shift to a 24-month cliff/delayed vesting for RSUs suggests the company is aggressively trying to improve retention or cash preservation by delaying equity issuance.
📋 Key Facts
- New RSU Tax Policy: Section 16 Officers will satisfy tax liabilities via share withholding rather than selling shares on the open market.
- Cash Bonus Plan: Established a new plan for executive officers with mid-year reviews (up to 35% payout in Q3 2025) and year-end payouts (up to 65% in Q1 2026).
- Performance Metrics: 2025 goals are tied to the BACKBEAT clinical study, Virtue Sirolimus AngioInfusion Balloon program milestones, and financial/operating objectives.
- Stretch Goals: Implementation of 'very difficult' stretch goals that can increase bonus achievement scores by up to 60%.
- Equity Award Policy: New policy for VP+ Officers allowing elections between stock options, RSUs, or a hybrid approach.
- Revised RSU Vesting: A new three-year vesting schedule with initial vesting commencing only after 24 months of service (33.33% at 24, 30, and 36 months).
Orchestra BioMed Holdings announced the appointment of Chris Cleary to the Board and Audit Committee, while simultaneously announcing the resignation of Eric Rose, M.D., from the Board.
🚩 Red Flags
- None identified; director resignation is mitigated by the transition to a strategic advisor role rather than a complete exit from company involvement.
📋 Key Facts
- Chris Cleary appointed as Class II director and Audit Committee member effective January 30, 2025.
- Board size increased from eight to nine with Mr. Cleary's appointment.
- Eric Rose, M.D., resigned from the Board effective February 3, 2025, transitioning to an Emeritus Board member and Strategic Advisor role.
- The Board is expected to decrease back to eight members following Dr. Rose's departure.
Orchestra BioMed Holdings entered into a new $100 million 'at-the-market' (ATM) sales agreement with TD Securities (USA) LLC. Simultaneously, the company terminated its existing $100 million sales agreement with Jefferies LLC to resolve research dissemination restrictions.
🚩 Red Flags
- Significant potential for equity dilution via the new $100M ATM offering.
- Frequent changes in sales agents/agreements (transitioning from Jefferies to TD Securities).
📋 Key Facts
- Entered into a Sales Agreement with TD Securities (USA) LLC on August 12, 2024.
- The new offering allows for the sale of common stock up to an aggregate price of $100,000,000 via 'at the market' methods.
- Terminated a prior Open Market Sale Agreement with Jefferies LLC dated May 15, 2024.
- Under the terminated Jefferies agreement, $15.5 million in shares had already been sold, leaving $84.5 million remaining.
- The termination of the Jefferies agreement was intended to eliminate SEC-related restrictions on research reports being published by Jefferies.
Orchestra BioMed Holdings, Inc. announced the appointment of John Mack to its Board of Directors and Audit Committee, effective July 29, 2024. This appointment increases the size of the Board from seven to eight directors.
📋 Key Facts
- John Mack appointed as Class I director, effective July 29, 2024.
- Mr. Mack also appointed to the Company's Audit Committee.
- Board size increased from seven to eight directors.
- Mr. Mack previously served as President of Cardiac Surgery for Medtronic, Inc. (retired Jan 2023).
- Compensation will follow the Director Compensation Policy outlined in the 2023 Form 10-K.
Orchestra BioMed Holdings, Inc. held its 2024 Annual Meeting of Stockholders on June 20, 2024. The meeting resulted in the successful election of two Class I directors and the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- Total shares entitled to vote: 35,786,497; Total shares represented at meeting: 28,647,942.
- Election of Class I Directors: Eric A. Rose, M.D. and Jason Aryeh were both elected to serve until the 2027 annual meeting.
- Ratification of Auditor: Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Orchestra BioMed Holdings, Inc. filed an 8-K to provide a copy of a slide presentation used at investor and industry conferences as part of its Regulation FD disclosure.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- Exhibit 99.1 contains an Investor Presentation.
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Orchestra BioMed Holdings, Inc. announced the scheduling of its first Annual Meeting of Stockholders for June 20, 2024. The filing outlines record dates and deadlines for shareholder proposals and director nominations.
📋 Key Facts
- Annual Meeting Date: Thursday, June 20, 2024.
- Record Date for stockholders: April 26, 2024.
- Deadline for Rule 14a-8 shareholder proposals: April 8, 2024.
- Deadline for director nominations/other business per Bylaws: April 8, 2024.
Orchestra BioMed Holdings, Inc. filed an 8-K to provide a copy of its investor presentation used at conferences and presentations via Item 7.01.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- An investor presentation was attached as Exhibit 99.1.
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liabilities.